NASA Logo

NTRS

NTRS - NASA Technical Reports Server

Back to Results
Role of carbonic anhydrase in bone - Plasma acetazolamide concentrations associated with inhibition of bone lossThe effects of acetazolamide and benzolamide on bone formation are examined. Solutions of acetazolamide and benzolamide with 1 M THAM/tris(hydromethyl)aminoethane/ or without 1 M THAM were injected subcutaneous with a minipump and into the food of Sprague-Dawley rats. The data reveal that for 8-day and 12-day infusions only acetazolamide combined with 1 M THAM caused any reduction in bone loss and there were no changes in body weights, food consumption and plasma calcium and phosphorus values. Following 8 days of infusion of acetazolamide with 1 M THAM at infusion rates of 0.5, 5.0, and 50 micrograms/hr, no reduction was detected at 0.5 microgram/hr, a 30 percent reduction occurred at 5.0 micrograms/hr and a 49 percent decrease at 50 micrograms/hr. In the benzolamide experiment it was observed that 0.5 percent of the solution in the food caused no reduction in bone loss; however, infusions with benzolamide plus 1 M THAM resulted in a bone loss reduction of 30 percent at 5.0 micrograms/hr, and a 49 percent decrease at 50 micrograms/hr. Acetazolamide levels in the plasma at 50 micrograms/hr doses are calculated as ranging from 99 ng/ml-223 ng/ml and as 46 ng/ml at 5 micrograms/hr doses.
Document ID
19860058716
Acquisition Source
Legacy CDMS
Document Type
Reprint (Version printed in journal)
Authors
Kenny, A. D.
(Texas Tech University, Health Science Center Lubbock, United States)
Date Acquired
August 12, 2013
Publication Date
January 1, 1985
Publication Information
Publication: Pharmacology
Volume: 31
ISSN: 0031-7012
Subject Category
Life Sciences (General)
Accession Number
86A43454
Funding Number(s)
CONTRACT_GRANT: NIH-AM-19475
CONTRACT_GRANT: NSG-2137
Distribution Limits
Public
Copyright
Other

Available Downloads

There are no available downloads for this record.
No Preview Available